Price Band of Gujarat Kidney and Super Speciality’s Initial Public Issue Set at Rs 108 – Rs 114 per Equity Share
FinTech BizNews Service
Mumbai, December 16, 2025: Gujarat Kidney and Super Speciality Ltd has fixed the price band of Rs 108/- to Rs 114/- per Equity Share of face value Rs 2/- each for its maiden initial public offer.
The Initial Public Issue (“IPO” or “Issue”) of the Company will open on Monday, December 22, 2025, for subscription and close on Wednesday, December 24, 2025. Investors can bid for a minimum of 128 Equity Shares and in multiples of 128 Equity Shares thereafter. Equity shares outstanding as on date 5,68,43,250 Equity Shares of Rs 2 each.
The IPO is a fresh issue of up to 2,20,00,000 equity shares.
The company is one of the regional healthcare companies located in the central region of
Gujarat and operates a chain of mid-sized multi-speciality hospitals, providing integrated
healthcare services, with a focus on secondary and tertiary care.
We on a consolidated basis, operate seven (07) multispeciality hospitals and four (04)
pharmacies operating within our Hospitals, Gujarat Kidney and Superspeciality Hospital
(Vadodara), Gujarat Multispeciality Hospital (Godhra), Raj Palmland Hospital Private Limited
(Bharuch), M/s. Surya Hospital and ICU (Borsad), Gujarat Surgical Hospital (Vadodara),
Ashwini Medical Centre (Anand), Ashwini Medical Store (Anand) and Apex Multispeciality &
Trauma Center (Bharuch) with a total bed capacity of 490 beds, approved bed capacity of
445 beds and operational bed capacity of 340 beds.
The company categorizes its healthcare services as secondary services (which are surgical
services) and tertiary Services (which are super speciality surgical services). Its hospitals are
providing integrated diagnostic services, either in-house, and pharmacies that cater to its
patients. The company has strategically focussed on the relatively under penetrated
healthcare market in Gujarat, India where it has a presence in four cities, which it believes
has provided it an understanding of regional nuances, patient culture and the mindset of
medical professionals and where there is under-penetration of quality and affordable
healthcare services.
The company’s revenue from operations was Rs 40.24 crore during the year ended on
March 31, 2025, and its net profit was Rs9.49 crore.
The company’s revenue from operations was Rs 15.26 crore during Three month period
ended June 30, 2025 and its net profit was Rs 5.40 crore.
Nirbhay Capital Services Private Limited is the book-running lead manager; and MUFG
Intime India Limited is the registrar of the offer.
The Offer is being made through the book-building process, wherein not more than 75% of
the net offer is allocated to qualified institutional buyers, and not more than 15% and 10%
of the net offer is assigned to non-institutional bidders and retail individual bidders
respectively.
